Nicotinamide mononucleotide supplementation modulates gut microbiota and metabolites to mitigate Alzheimer's disease pathology in APP/PS1 mice.

Zhou H, Zhao X, Li Y, Wang Y, Zhang S, Xu H, Sui S, Wang Q, He Y, Gu J

Journal of Alzheimer's disease : JAD10 Mar 2026

PMID41805251DOI10.1177/13872877261422502PepBankPUB-41805251

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In APP/PS1 mice, NMN altered gut microbial composition.
In plain wordsIn mice with an Alzheimer's disease model, NMN changed gut bacteria composition.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Direction not reportedGut microbial composition
Study
mousen: not reported in source
APP/PS1 mice
Outcome group
Gut microbiota · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
ResultsNMN administration significantly altered gut microbial composition and fecal metabolite profiles, leading to improvements in colon damage and AD-related neuropathology.
1 context sentence(design, population, supporting numbers)
Summary · context
ObjectiveTo explore the therapeutic potential of NMN supplementation in regulating AD pathology as well as gut microbiome dynamics, APP/PS1 transgenic mouse models were employed in the research.MethodsMetagenomic and metabolomics analysis were conducted to assess modifications in the intestinal micr…
Report a problemFND-4180525101
02AnimalAnimal study (in vivo)Efficacy outcome
In APP/PS1 mice, NMN altered fecal metabolite profiles.
In plain wordsIn mice with an Alzheimer's disease model, NMN changed fecal metabolite profiles.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Direction not reportedFecal metabolite profiles
Study
mousen: not reported in source
APP/PS1 mice
Outcome group
Metabolic pathways and metabolomics · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
ResultsNMN administration significantly altered gut microbial composition and fecal metabolite profiles, leading to improvements in colon damage and AD-related neuropathology.
1 context sentence(design, population, supporting numbers)
Summary · context
ObjectiveTo explore the therapeutic potential of NMN supplementation in regulating AD pathology as well as gut microbiome dynamics, APP/PS1 transgenic mouse models were employed in the research.MethodsMetagenomic and metabolomics analysis were conducted to assess modifications in the intestinal micr…
Report a problemFND-4180525102
03AnimalAnimal study (in vivo)Efficacy outcome
In APP/PS1 mice, NMN improved colon damage.
In plain wordsIn mice with an Alzheimer's disease model, NMN reduced colon damage.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseColon damage
Study
mousen: not reported in source
APP/PS1 mice
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
ResultsNMN administration significantly altered gut microbial composition and fecal metabolite profiles, leading to improvements in colon damage and AD-related neuropathology.
1 context sentence(design, population, supporting numbers)
Summary · context
ObjectiveTo explore the therapeutic potential of NMN supplementation in regulating AD pathology as well as gut microbiome dynamics, APP/PS1 transgenic mouse models were employed in the research.MethodsMetagenomic and metabolomics analysis were conducted to assess modifications in the intestinal micr…
Report a problemFND-4180525103
04AnimalAnimal study (in vivo)Efficacy outcome
In APP/PS1 mice, NMN improved AD-related neuropathology.
In plain wordsIn mice with an Alzheimer's disease model, NMN reduced disease-related brain damage.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseAD-related neuropathology
Study
mousen: not reported in source
APP/PS1 mice
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
ResultsNMN administration significantly altered gut microbial composition and fecal metabolite profiles, leading to improvements in colon damage and AD-related neuropathology.
1 context sentence(design, population, supporting numbers)
Summary · context
ObjectiveTo explore the therapeutic potential of NMN supplementation in regulating AD pathology as well as gut microbiome dynamics, APP/PS1 transgenic mouse models were employed in the research.MethodsMetagenomic and metabolomics analysis were conducted to assess modifications in the intestinal micr…
Report a problemFND-4180525104
05AnimalAnimal study (in vivo)Efficacy outcome
In APP/PS1 mice, NMN increased Bacteroides abundance.
In plain wordsIn mice with an Alzheimer's disease model, NMN increased Bacteroides gut bacteria.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseBacteroides abundance
Study
mousen: not reported in source
APP/PS1 mice
Outcome group
Gut microbiota · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Key findings include the restoration of gut microbial balance, particularly increasing Bacteroides abundance, and the modulation of metabolites involved in lipid metabolism.
1 context sentence(design, population, supporting numbers)
Summary · context
ObjectiveTo explore the therapeutic potential of NMN supplementation in regulating AD pathology as well as gut microbiome dynamics, APP/PS1 transgenic mouse models were employed in the research.MethodsMetagenomic and metabolomics analysis were conducted to assess modifications in the intestinal micr…
Report a problemFND-4180525105
06AnimalAnimal study (in vivo)Efficacy outcome
In APP/PS1 mice, NMN modulated metabolites involved in lipid metabolism.
In plain wordsIn mice with an Alzheimer's disease model, NMN changed metabolites involved in fat metabolism.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Direction not reportedLipid-related metabolites
Study
mousen: not reported in source
APP/PS1 mice
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Key findings include the restoration of gut microbial balance, particularly increasing Bacteroides abundance, and the modulation of metabolites involved in lipid metabolism.
1 context sentence(design, population, supporting numbers)
Summary · context
ObjectiveTo explore the therapeutic potential of NMN supplementation in regulating AD pathology as well as gut microbiome dynamics, APP/PS1 transgenic mouse models were employed in the research.MethodsMetagenomic and metabolomics analysis were conducted to assess modifications in the intestinal micr…
Report a problemFND-4180525106
07AnimalAnimal study (in vivo)Mechanism
In APP/PS1 mice, NMN regulated ferroptosis.
In plain wordsIn mice with an Alzheimer's disease model, NMN regulated ferroptosis, a form of cell death.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Direction not reportedFerroptosis
Study
mousen: not reported in source
APP/PS1 mice
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Furthermore, NMN was found to regulate ferroptosis, improving gut barrier function in AD mice, which were mediated through gut-brain communication pathways.
1 context sentence(design, population, supporting numbers)
Summary · context
ObjectiveTo explore the therapeutic potential of NMN supplementation in regulating AD pathology as well as gut microbiome dynamics, APP/PS1 transgenic mouse models were employed in the research.MethodsMetagenomic and metabolomics analysis were conducted to assess modifications in the intestinal micr…
Report a problemFND-4180525107
08AnimalAnimal study (in vivo)Efficacy outcome
In APP/PS1 mice, NMN improved gut barrier function.
In plain wordsIn mice with an Alzheimer's disease model, NMN improved the gut barrier.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseGut barrier function
Study
mousen: not reported in source
APP/PS1 mice
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Furthermore, NMN was found to regulate ferroptosis, improving gut barrier function in AD mice, which were mediated through gut-brain communication pathways.
1 context sentence(design, population, supporting numbers)
Summary · context
ObjectiveTo explore the therapeutic potential of NMN supplementation in regulating AD pathology as well as gut microbiome dynamics, APP/PS1 transgenic mouse models were employed in the research.MethodsMetagenomic and metabolomics analysis were conducted to assess modifications in the intestinal micr…
Report a problemFND-4180525108
09AnimalAnimal study (in vivo)Efficacy outcome
In APP/PS1 mice, NMN enhanced hippocampal ATP production.
In plain wordsIn mice with an Alzheimer's disease model, NMN increased ATP production in the hippocampus.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseATP production
Study
mousen: not reported in source
APP/PS1 mice
Outcome group
Mitochondrial function · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
NMN supplementation also enhanced ATP production, mitochondrial function, and synaptic density in the hippocampus while reducing oxidative stress and Aβ accumulation in the brain.
1 context sentence(design, population, supporting numbers)
Summary · context
ObjectiveTo explore the therapeutic potential of NMN supplementation in regulating AD pathology as well as gut microbiome dynamics, APP/PS1 transgenic mouse models were employed in the research.MethodsMetagenomic and metabolomics analysis were conducted to assess modifications in the intestinal micr…
Report a problemFND-4180525109
10AnimalAnimal study (in vivo)Efficacy outcome
In APP/PS1 mice, NMN enhanced hippocampal mitochondrial function.
In plain wordsIn mice with an Alzheimer's disease model, NMN improved mitochondrial function in the hippocampus.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseMitochondrial function
Study
mousen: not reported in source
APP/PS1 mice
Outcome group
Mitochondrial function · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
NMN supplementation also enhanced ATP production, mitochondrial function, and synaptic density in the hippocampus while reducing oxidative stress and Aβ accumulation in the brain.
1 context sentence(design, population, supporting numbers)
Summary · context
ObjectiveTo explore the therapeutic potential of NMN supplementation in regulating AD pathology as well as gut microbiome dynamics, APP/PS1 transgenic mouse models were employed in the research.MethodsMetagenomic and metabolomics analysis were conducted to assess modifications in the intestinal micr…
Report a problemFND-4180525110
11AnimalAnimal study (in vivo)Efficacy outcome
In APP/PS1 mice, NMN enhanced hippocampal synaptic density.
In plain wordsIn mice with an Alzheimer's disease model, NMN increased connection density in the hippocampus.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseSynaptic density
Study
mousen: not reported in source
APP/PS1 mice
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
NMN supplementation also enhanced ATP production, mitochondrial function, and synaptic density in the hippocampus while reducing oxidative stress and Aβ accumulation in the brain.
1 context sentence(design, population, supporting numbers)
Summary · context
ObjectiveTo explore the therapeutic potential of NMN supplementation in regulating AD pathology as well as gut microbiome dynamics, APP/PS1 transgenic mouse models were employed in the research.MethodsMetagenomic and metabolomics analysis were conducted to assess modifications in the intestinal micr…
Report a problemFND-4180525111
12AnimalAnimal study (in vivo)Efficacy outcome
In APP/PS1 mice, NMN reduced brain oxidative stress.
In plain wordsIn mice with an Alzheimer's disease model, NMN reduced oxidative stress in the brain.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseOxidative stress
Study
mousen: not reported in source
APP/PS1 mice
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
NMN supplementation also enhanced ATP production, mitochondrial function, and synaptic density in the hippocampus while reducing oxidative stress and Aβ accumulation in the brain.
1 context sentence(design, population, supporting numbers)
Summary · context
ObjectiveTo explore the therapeutic potential of NMN supplementation in regulating AD pathology as well as gut microbiome dynamics, APP/PS1 transgenic mouse models were employed in the research.MethodsMetagenomic and metabolomics analysis were conducted to assess modifications in the intestinal micr…
Report a problemFND-4180525112
13AnimalAnimal study (in vivo)Efficacy outcome
In APP/PS1 mice, NMN reduced brain Aβ accumulation.
In plain wordsIn mice with an Alzheimer's disease model, NMN reduced amyloid accumulation in the brain.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseAβ accumulation
Study
mousen: not reported in source
APP/PS1 mice
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
NMN supplementation also enhanced ATP production, mitochondrial function, and synaptic density in the hippocampus while reducing oxidative stress and Aβ accumulation in the brain.
1 context sentence(design, population, supporting numbers)
Summary · context
ObjectiveTo explore the therapeutic potential of NMN supplementation in regulating AD pathology as well as gut microbiome dynamics, APP/PS1 transgenic mouse models were employed in the research.MethodsMetagenomic and metabolomics analysis were conducted to assess modifications in the intestinal micr…
Report a problemFND-4180525113
14AnimalAnimal study (in vivo)Efficacy outcome
In APP/PS1 mice, NMN alleviated cognitive deficits.
In plain wordsIn mice with an Alzheimer's disease model, NMN reduced cognitive deficits.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseCognitive deficits
Study
mousen: not reported in source
APP/PS1 mice
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Ultimately, these multi-faceted improvements collectively alleviated cognitive deficits in AD mice.
1 context sentence(design, population, supporting numbers)
Summary · context
ObjectiveTo explore the therapeutic potential of NMN supplementation in regulating AD pathology as well as gut microbiome dynamics, APP/PS1 transgenic mouse models were employed in the research.MethodsMetagenomic and metabolomics analysis were conducted to assess modifications in the intestinal micr…
Report a problemFND-4180525114

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Nicotinamide mononucleotide supplementation modulates gut microbiota and metabolites to mitigate Alzheimer's disease pathology in APP/PS1 mice.

Summary

Results from this study14

Version history

Subjects

Publication types

MeSH terms

Keywords